Sinovac Completes Immunization Schedule in the Phase I Clinical Trial of its Proprietary Avian Influenza Vaccine (H5N1)

Sinovac Completes Immunization Schedule in the Phase I Clinical Trial of its Proprietary Avian Influenza Vaccine (H5N1)

April 10, 2006

    BEIJING, April 10 /Xinhua-PRNewswire/ -- Sinovac
Biotech Ltd. (AMEX: SVA) announced today that all 120
volunteers in the Phase I clinical trial of its avian
influenza vaccine (H5N1) have completed the two shot
regimen of either the vaccine or a placebo.  

    All 120 volunteers (aged 18 - 60 years) in the clinical
trial were thoroughly evaluated and medically documented
prior to entering the vaccination program.  The clinical
trial was conducted on a 0 and 28 day dose immunization
schedule.  Sinovac expects to take blood samples from
volunteers to analyze the antibody growth and effectiveness
of the vaccine. 

    Sinovac's CEO, Mr. Weidong Yin commented,
"Everything is progressing as we expected.  Teaming up
with the China CDC is extremely beneficial.  We are working
hard together to produce a safe and effective vaccine that
I believe will benefit the whole world."

    About Sinovac 

    Sinovac Biotech Ltd. is a world-class Chinese
biopharmaceutical company, focused on research, development
and commercialization of vaccines designed to combat human
infectious diseases.  Sinovac's vaccines include
Healive(TM) (hepatitis A), Bilive(TM) (hepatitis B) and
Anflu(TM) (influenza).  Sinovac has vaccines in clinical
trials to combat avian influenza (bird flu) and SARS.

    Additional information about Sinovac is available on
the Company website, http://www.sinovac.com and the Sinovac
Investor Relations website,
http://finance.groups.yahoo.com/group/Sinovac_Biotech_IR .

    To be added to our distribution list, please email:
[e-mail] 

    Safe Harbor Statement

    This announcement contains forward-looking statements. 
These statements are made under the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform
Act of 1995.  These forward-looking statements can be
identified by words or phrases such as "will,"
"expects," "anticipates,"
"future," "intends," "plans,"
"believes," "estimates" and similar
statements.  Among other things, the business outlook and
quotations from management in this press release contain
forward-looking statements.  Statements that are not
historical facts, including statements about Sinovac's
beliefs and expectations, are forward-looking statements. 
Forward-looking statements involve inherent risks and
uncertainties.  A number of important factors could cause
actual results to differ materially from those contained in
any forward-looking statement.  Sinovac does not undertake
any obligation to update any forward-looking statement,
except as required under applicable law.

    For more information, please contact: 

     Craig H. Bird
     Segue Investor Relations
     Tel:   [phone] or Toll Free: [phone]
(North America)
     Email: [e-mail]

SOURCE  Sinovac Biotech Ltd.